Reveal Genomics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
Buyout/LBO
- (Announced)
- Investors
-
2
Reveal Genomics General Information
Description
Developer of genomic diagnostic tests designed for selecting optimal treatment strategies for patients. The company's technology utilizes computational analysis and machine learning to decode biomarkers through biopsy-based approaches, enabling oncology patients to receive personalized treatment strategies based on integrated genomic and clinical data.
Contact Information
Website
www.reveal-genomics.comCorporate Office
- Carrer de Villarroel, 170.
- Escala 2, Planta 5
- 08036 Barcelona
- Spain
Corporate Office
- Carrer de Villarroel, 170.
- Escala 2, Planta 5
- 08036 Barcelona
- Spain
Reveal Genomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Buyout/LBO (Add-on) | 16-Oct-2026 | Announced | Generating Revenue | |||
| 4. Early Stage VC (Series A) | Cancelled | Generating Revenue | ||||
| 3. Accelerator/Incubator | 05-May-2022 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 31-Dec-2021 | $5.65M | $6.25M | Completed | Generating Revenue | |
| 1. Early Stage VC | 19-Mar-2021 | $601K | $601K | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Reveal Genomics Patents
Reveal Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024408468-A1 | In vitro method for predicting longevity in cancer survivors | Pending | 22-Dec-2023 | ||
| EP-4829056-A1 | In vitro method for predicting longevity in cancer survivors | Pending | 22-Dec-2023 | ||
| WO-2025131824-A1 | In vitro method for predicting longevity in cancer survivors | Inactive | 22-Dec-2023 | ||
| EP-4574999-A1 | In vitro method for predicting longevity in patients suffering from breast cancer | Inactive | 22-Dec-2023 | ||
| AU-2024297553-A1 | In vitro method for the prognosis of patients suffering from triple-negative breast cancer | Pending | 07-Jul-2023 | C12Q1/6886 |
Reveal Genomics Signals
Reveal Genomics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Academy for Women Entrepreneurs - Catalonia | Accelerator/Incubator | |||
| Universitat Autònoma de Barcelona | University | Minority |
Reveal Genomics FAQs
-
When was Reveal Genomics founded?
Reveal Genomics was founded in 2020.
-
Where is Reveal Genomics headquartered?
Reveal Genomics is headquartered in Barcelona, Spain.
-
What is the size of Reveal Genomics?
Reveal Genomics has 23 total employees.
-
What industry is Reveal Genomics in?
Reveal Genomics’s primary industry is Decision/Risk Analysis.
-
Is Reveal Genomics a private or public company?
Reveal Genomics is a Private company.
-
What is Reveal Genomics’s current revenue?
The current revenue for Reveal Genomics is .
-
How much funding has Reveal Genomics raised over time?
Reveal Genomics has raised $6.25M.
-
Who are Reveal Genomics’s investors?
Academy for Women Entrepreneurs - Catalonia and Universitat Autònoma de Barcelona have invested in Reveal Genomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process